SXTP
Price
$1.31
Change
-$0.03 (-2.24%)
Updated
Jul 25 closing price
Capitalization
4.23M
16 days until earnings call
XFOR
Price
$1.82
Change
-$0.01 (-0.55%)
Updated
Jul 25 closing price
Capitalization
13.07M
3 days until earnings call
Interact to see
Advertisement

SXTP vs XFOR

Header iconSXTP vs XFOR Comparison
Open Charts SXTP vs XFORBanner chart's image
60 Degrees Pharmaceuticals
Price$1.31
Change-$0.03 (-2.24%)
Volume$109.91K
Capitalization4.23M
X4 Pharmaceuticals
Price$1.82
Change-$0.01 (-0.55%)
Volume$1.55M
Capitalization13.07M
SXTP vs XFOR Comparison Chart in %
Loading...
SXTP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SXTP vs. XFOR commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SXTP is a Hold and XFOR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (SXTP: $1.31 vs. XFOR: $1.82)
Brand notoriety: SXTP and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SXTP: 13% vs. XFOR: 170%
Market capitalization -- SXTP: $4.23M vs. XFOR: $13.07M
SXTP [@Biotechnology] is valued at $4.23M. XFOR’s [@Biotechnology] market capitalization is $13.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SXTP’s FA Score shows that 1 FA rating(s) are green whileXFOR’s FA Score has 2 green FA rating(s).

  • SXTP’s FA Score: 1 green, 4 red.
  • XFOR’s FA Score: 2 green, 3 red.
According to our system of comparison, XFOR is a better buy in the long-term than SXTP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SXTP’s TA Score shows that 4 TA indicator(s) are bullish while XFOR’s TA Score has 5 bullish TA indicator(s).

  • SXTP’s TA Score: 4 bullish, 5 bearish.
  • XFOR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XFOR is a better buy in the short-term than SXTP.

Price Growth

SXTP (@Biotechnology) experienced а -9.03% price change this week, while XFOR (@Biotechnology) price change was +27.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

SXTP is expected to report earnings on Aug 13, 2025.

XFOR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XFOR($13.1M) has a higher market cap than SXTP($4.23M). SXTP YTD gains are higher at: -79.690 vs. XFOR (-91.730). XFOR has higher annual earnings (EBITDA): 25.2M vs. SXTP (-10.19M). XFOR has more cash in the bank: 87M vs. SXTP (3.45M). SXTP has less debt than XFOR: SXTP (155K) vs XFOR (78M). XFOR has higher revenues than SXTP: XFOR (31.4M) vs SXTP (665K).
SXTPXFORSXTP / XFOR
Capitalization4.23M13.1M32%
EBITDA-10.19M25.2M-40%
Gain YTD-79.690-91.73087%
P/E RatioN/A0.86-
Revenue665K31.4M2%
Total Cash3.45M87M4%
Total Debt155K78M0%
FUNDAMENTALS RATINGS
XFOR: Fundamental Ratings
XFOR
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
12
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SXTPXFOR
RSI
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
86%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
SXTP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GAUZ7.320.36
+5.17%
Gauzy Ltd
AMRK22.090.21
+0.96%
A-Mark Precious Metals
PFG81.050.17
+0.21%
Principal Financial Group
NSA31.40-0.06
-0.19%
National Storage Affiliates Trust
LIXT4.11-0.18
-4.20%
Lixte Biotechnology Holdings

SXTP and

Correlation & Price change

A.I.dvisor tells us that SXTP and VRAX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SXTP and VRAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SXTP
1D Price
Change %
SXTP100%
-2.24%
VRAX - SXTP
25%
Poorly correlated
-4.42%
MLYS - SXTP
23%
Poorly correlated
+0.42%
ABCZF - SXTP
23%
Poorly correlated
N/A
XFOR - SXTP
23%
Poorly correlated
-0.55%
PASG - SXTP
23%
Poorly correlated
+29.84%
More

XFOR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with ABP. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then ABP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
-0.55%
ABP - XFOR
50%
Loosely correlated
+18.53%
HOFBF - XFOR
35%
Loosely correlated
N/A
CRDF - XFOR
33%
Poorly correlated
-4.11%
INM - XFOR
32%
Poorly correlated
-1.49%
ABSI - XFOR
31%
Poorly correlated
N/A
More